Sellar lesions refer to a spectrum of space-occupying masses arising within the sphenoid sellar region at the skull base, including pituitary adenomas, craniopharyngiomas, germ cell tumors and other subtypes. As one of the most common intracranial tumor sites, sellar lesions account for 15%–20% of all intracranial neoplasms, with benign pituitary adenomas constituting the overwhelming majority. Despite its tiny volume, this bony cavity houses the body’s master endocrine organ — the pituitary gland. Directly superior to it lies the optic chiasm, a vital structure of the visual pathway, while the bilateral cavernous sinuses (housing critical blood vessels and cranial nerves) flank the sellar fossa. For this anatomical reason, even small lesions may trigger complex endocrine derangements and compressive neurological symptoms. Advances in modern imaging have steadily elevated detection rates; MRI screening reveals incidental asymptomatic pituitary microadenomas in 10%–20% of the general population. Early identification and precise intervention are critical to optimizing long-term patient prognosis.

1. Anatomical Structure and Physiological Significance of the Sellar Fossa

The sellar fossa is a concave bony depression formed on the superior portion of the sphenoid body, named the sella turcica for its saddle-like contour. This osseous compartment measures approximately 8–10 mm anteroposteriorly, 10–16 mm transversely and 6–9 mm in depth, supporting irreplaceable endocrine function despite its diminutive size. The pea-sized pituitary gland resides within the fossa: the gland weighs 0.5–0.6 g in adult males, slightly heavier in females, and may nearly double to 1 g during pregnancy.

A thin pituitary stalk connects the gland to the hypothalamus, forming the hypothalamic-pituitary axis that governs core life processes including growth, development, metabolism and reproduction. The pituitary is anatomically divided into the adenohypophysis and neurohypophysis. The adenohypophysis secretes growth hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and other key hormones. The neurohypophysis stores and releases antidiuretic hormone (ADH) and oxytocin.

A tough dural membrane called the diaphragma sellae covers the roof of the sellar fossa, perforated centrally to allow passage of the pituitary stalk. Intact diaphragma sellae maintains intracranial pressure homeostasis; defects predispose patients to empty sella syndrome. Lateral to the sellar fossa sit the cavernous sinuses, which contain the internal carotid artery plus the oculomotor, trochlear, abducens and ophthalmic trigeminal nerves. This anatomical relationship explains the frequent presentation of extraocular muscle palsies and facial sensory deficits in sellar mass patients.

The spatial relationship between the sellar fossa and optic chiasm carries vital clinical relevance. The optic chiasm lies roughly 10 mm anterosuperior to the fossa. Suprasellar extension of pituitary tumors first compresses central chiasmal fibers, producing the pathognomonic bitemporal hemianopia. This anatomy clarifies why visual deterioration is the initial presenting complaint for most patients with pituitary macroadenomas.

2. Clinical Manifestations and Symptom Analysis of Sellar Lesions

Symptom profiles of sellar lesions are highly heterogeneous, stemming from three primary mechanisms: hormonal hypersecretion, mass effect and compression of adjacent neurovascular structures. The sequence and severity of symptoms correlate closely with lesion histology, size and growth trajectory.

Endocrine Dysfunction (Hallmark of Functional Pituitary Adenomas)

Growth hormone-secreting adenomas: Gigantism in pediatric patients; acromegaly in adults, manifesting as enlarged hands and feet, coarse facial features and soft tissue overgrowth, frequently complicated by hypertension, diabetes mellitus and cardiovascular disease.

ACTH-secreting adenomas: Cushing’s disease, characterized by central obesity, moon facies, buffalo hump and cutaneous striae.

Prolactinomas: Amenorrhea-galactorrhea syndrome in women; diminished libido and infertility in men.

Compressive Neurological Symptoms

Superior extension compresses the optic chiasm, causing visual loss and visual field defects. Early involvement typically affects the superior temporal quadrants, progressing to complete bitemporal hemianopia.

Lateral cavernous sinus invasion induces oculomotor nerve palsy, presenting as ptosis and restricted ocular motility.

Giant tumors penetrating the diaphragma sellae upward compress the third ventricle, triggering obstructive hydrocephalus and elevated intracranial pressure.

Distinct Clinical Syndromes

Empty sella syndrome: Herniation of subarachnoid space into the sellar fossa leading to pituitary compression and atrophy. Most prevalent in multiparous women; the majority remain asymptomatic, while a subset develops headache, visual impairment and mild hypopituitarism.

Pituitary apoplexy: Surgical emergency caused by intratumoral hemorrhage or infarction, featuring abrupt severe headache, rapid visual loss and ophthalmoplegia requiring urgent decompressive surgery.

Approximately 5%–10% of sellar lesions are entirely asymptomatic, detected incidentally on imaging as “incidentalomas”. Though most are benign, regular serial surveillance is mandatory to monitor dynamic growth, especially for lesions exceeding 1 cm in diameter.

3. Comprehensive Diagnostic Workup for Sellar Lesions

Definitive diagnosis integrates endocrine testing, high-resolution imaging and ophthalmic visual function assessment to construct a complete clinical-pathological profile. Standardized workflows facilitate accurate lesion characterization and guide therapeutic decision-making.

Imaging Evaluation (Core Localization Modality)

Contrast-enhanced pituitary MRI is the first-line examination. Multiplanar sequences and superior soft tissue resolution clearly delineate mass boundaries and adjacent anatomical relations. Microadenomas typically demonstrate hypointensity on T1-weighted sequences with weaker enhancement than normal pituitary parenchyma, creating a focal filling defect. Macroadenomas commonly extend suprasellarly, forming the classic “snowman” or figure-8 sign. CT excels at visualizing sellar bony architecture and calcification, particularly valuable for differentiating craniopharyngiomas and meningiomas. CTA/MRA or cerebral angiography delineates tumor-vessel interfaces to inform preoperative surgical planning.

Endocrine Functional Testing (Key to Histological Subtyping)

Basal hormonal panels include PRL, GH, IGF-1, ACTH, serum cortisol, TSH, free T4 and gonadal steroids. Provocative dynamic tests are indicated for equivocal cases: oral glucose GH suppression test for acromegaly, overnight high-dose dexamethasone suppression test for Cushing’s disease. Full assessment of anterior pituitary hormonal reserve stratifies disease severity and predicts long-term prognosis.

Visual Function Assessment (Indispensable Routine Workup)

Standard ophthalmic evaluation covers visual acuity, automated perimetry and fundoscopy. Automated perimetry precisely quantifies the scope and severity of field loss. Visual evoked potentials (VEPs) objectively quantify optic pathway integrity and serve as a prognostic surgical biomarker. Serial perimetry for asymptomatic macroadenomas enables early detection of subclinical chiasmal compression.

Pathological Diagnosis (Gold Standard for Final Confirmation)

Tissue specimens harvested via transsphenoidal resection undergo routine histopathology, immunohistochemical staining to identify hormone-secreting subtypes, and Ki-67 proliferation index measurement to grade tumor proliferative activity. Advances in molecular pathology enable refined classification: GH adenomas are stratified by GSP mutation status, which correlates directly with responsiveness to medical therapy.

4. Therapeutic Strategies for Sellar Space-Occupying Lesions

Treatment follows an individualized framework, combining lesion subtype, size, endocrine activity and patient comorbidities to formulate multimodal regimens. Core therapeutic goals include relief of mass effect, normalization of excess hormone secretion, preservation of intact native pituitary function and prevention of recurrence.

Surgical Resection (First-Line for Most Symptomatic Pituitary Tumors)

Minimally invasive transnasal transsphenoidal surgery is the dominant modern approach, offered via microscopic or endoscopic corridors. This extradural nasal route eliminates the need for craniotomy, accessing the sella through natural nasal passages with minimal tissue trauma and rapid postoperative recovery.

•Cure rate for microadenomas: 80%–90%

•Gross total resection rate for macroadenomas: 50%–70%

• Postoperative visual improvement rate for optic nerve compression: >85%

Craniotomy is reserved for giant, irregular lesions with extensive suprasellar or retrosellar extension, offering wider surgical exposure at the cost of greater operative trauma.

Medical Therapy (High Efficacy for Select Functional Subtypes)

Dopamine agonists (e.g., cabergoline): First-line for prolactinomas, normalizing PRL levels in 80%–90% of microadenomas and 60%–70% of macroadenomas.

Somatostatin analogues (octreotide, lanreotide): Used for preoperative debulking or adjuvant control of GH adenomas, achieving biochemical remission in 50%–60% of patients.

Targeted agents for Cushing’s disease (pasireotide, osilodrostat): Novel therapeutic options for medically refractory cases.

Radiotherapy

Indicated for postoperative residual, recurrent or surgically inaccessible lesions.

Conventional fractionated radiotherapy: 85%–90% long-term tumor growth control, though hormonal normalization proceeds slowly and hypopituitarism is a common late adverse effect.

Stereotactic radiosurgery (Gamma Knife): Precise focal high-dose irradiation, suitable for residual lesions separated by ≥3 mm from the optic apparatus.

Potential radiation-related complications include radiation necrosis, cognitive decline and elevated secondary intracranial neoplasm risk, requiring strict adherence to formal eligibility criteria.

Long-Term Surveillance & Follow-Up

Serial endocrine testing and imaging constitute a permanent component of disease management. The first comprehensive re-evaluation occurs 3–6 months postoperatively; subsequent annual or biennial surveillance is scheduled based on disease stability.

Asymptomatic incidentalomas <1 cm: Conservative observational management.

Lesions >1 cm or abutting the optic chiasm: Surgical intervention recommended.

Patients with permanent hypopituitarism require lifelong individualized hormone replacement (thyroxine, glucocorticoids, sex steroids), with regular titration to avoid under- or over-replacement.

5. Frequently Asked Clinical Questions

Q1: Are sellar lesion surgeries highly technically challenging?

Operative difficulty varies by tumor size, growth pattern and histology. Transnasal transsphenoidal minimally invasive resection is the standard approach, delivering excellent outcomes (>80% success rate) for purely intrasellar or inferior sphenoid-extending masses. Giant invasive lesions or tumors adherent to the internal carotid artery carry substantially higher procedural complexity and require specialized high-volume pituitary neurosurgical teams. Overall, widespread adoption of intraoperative neuronavigation and endoscopy has drastically improved surgical safety and efficacy.

Q2: What clinical manifestations occur with sellar lesions?

Symptoms fall into two major categories: endocrine derangements and compressive neurological deficits.

Endocrine manifestations: Acromegaly (GH adenoma), Cushing’s syndrome (ACTH adenoma), amenorrhea-galactorrhea (prolactinoma), etc.

Neurological manifestations: Chronic headache, reduced visual acuity, bitemporal hemianopia.

Pituitary apoplexy may trigger sudden catastrophic headache and acute blindness. Roughly 10% of patients remain completely asymptomatic at presentation.

Q3: What tumor subtypes arise within the sellar fossa?

Pituitary adenomas account for over 85% of all sellar masses, overwhelmingly benign. Other differential diagnoses include calcified craniopharyngiomas, Rathke’s cleft cysts, meningiomas and germ cell tumors. Metastatic lesions and inflammatory sellar disease are rare. Final diagnosis requires integrated correlation of imaging, endocrine panels and surgical histopathology.